CGH
RGNX icon

Crossmark Global Holdings’s Regenxbio RGNX Stock Holding History

Crossmark Global Holdings’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,350
Closed -$392K – 1451
2021
Q3 		$392K Buy
9,350
+80
+0.9% +$2.88K 0.01% 1046
2021
Q2 		$360K Buy
9,270
+20
+0.2% +$715 0.01% 1085
2021
Q1 		$316K Buy
9,250
+360
+4% +$15.4K 0.01% 1140
2020
Q4 		$403K Buy
+8,890
New +$311K 0.01% 944
2019
Q3 		– Sell
-4,870
Closed -$250K – 1370
2019
Q2 		$250K Sell
4,870
-360
-7% -$18K 0.01% 1179
2019
Q1 		$300K Buy
5,230
+120
+2% +$5.94K 0.01% 1117
2018
Q4 		$214K Buy
5,110
+2,300
+82% +$135K 0.01% 1258
2018
Q3 		$212K Buy
+2,810
New +$202K 0.01% 1518

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crossmark Global Holdings's RGNX Position: Q4 2021 in Review

Crossmark Global Holdings sold out of Regenxbio (RGNX) in Q4 2021, closing a stake of 9,350 shares — an estimated $392K sold.

Crossmark Global Holdings first reported a position in RGNX in Q3 2018 and held it in 8 quarters. The position peaked at $403K in Q4 2020. 172 funds tracked by Wall St. Rank hold RGNX as of Q4 2021.

  • Crossmark Global Holdings reported no remaining Regenxbio position as of Q4 2021 after selling out during the quarter.
  • Crossmark Global Holdings sold 9,350 Regenxbio shares in Q4 2021, an estimated $392K.
  • Crossmark Global Holdings first reported a position in Regenxbio in Q3 2018 and held it in 8 quarters.
  • Crossmark Global Holdings's Regenxbio position peaked at $403K in Q4 2020.
  • 172 funds tracked by Wall St. Rank held Regenxbio as of Q4 2021.

Based on Crossmark Global Holdings's 13F filing for Q4 2021, filed 10 Jan 2022.